

浏览全部资源
扫码关注微信
1.北京中医药大学 中医学院,北京 100029
2.北京中医药大学 证候与方剂基础研究教育部 重点实验室,北京 100029
3.广州中医药大学 中药学院,广州 510006
Received:22 October 2025,
Revised:2025-12-22,
Accepted:24 December 2025,
Online First:29 December 2025,
Published:20 May 2026
移动端阅览
孟敬轲,刘素素,高攀等.丹荷颗粒对混合型高脂血症大鼠氧化应激的调控作用[J].中国实验方剂学杂志,2026,32(10):112-122.
MENG Jingke,LIU Susu,GAO Pan,et al.Regulatory Effect of Danhe Granules on Oxidative Stress in Rats with Mixed Hyperlipidemia[J].Chinese Journal of Experimental Traditional Medical Formulae,2026,32(10):112-122.
孟敬轲,刘素素,高攀等.丹荷颗粒对混合型高脂血症大鼠氧化应激的调控作用[J].中国实验方剂学杂志,2026,32(10):112-122. DOI: 10.13422/j.cnki.syfjx.20252505.
MENG Jingke,LIU Susu,GAO Pan,et al.Regulatory Effect of Danhe Granules on Oxidative Stress in Rats with Mixed Hyperlipidemia[J].Chinese Journal of Experimental Traditional Medical Formulae,2026,32(10):112-122. DOI: 10.13422/j.cnki.syfjx.20252505.
目的
2
基于网络药理学、动物和细胞实验探讨丹荷颗粒治疗混合型高脂血症的机制。
方法
2
利用中药系统药理学数据库与分析平台(TCMSP)、传统中药百科全书(ETCM)等数据库筛选丹荷颗粒活性成分及靶点,通过基因卡数据库(GeneCard)获取混合型高脂血症相关靶点,取交集后进行基因本体论功能注释(GO)及京都基因与基因组百科全书通路富集分析(KEGG);采用棕榈酸(PA)诱导人肝癌细胞(HepG2)建立高脂模型,给予丹荷颗粒干预,检测细胞内脂质含量、氧化应激水平;建立混合型高脂血症大鼠模型,设丹荷颗粒低、中、高剂量组(1.134、2.268、4.536 g·kg
-1
)及阳性药普伐他汀钠组(4.020 mg·kg
-1
),干预8周后检测血清脂质水平、炎症因子、氧化应激及肝组织脂质代谢关键蛋白表达。
结果
2
网络药理学筛选出丹荷颗粒与混合型高脂血症交集靶点93个,过氧化物酶体增生激活受体
γ
(PPARG)、过氧化物酶体增殖物激活受体
α
(PPARA)、肿瘤坏死因子(TNF)、白细胞介素(IL)-6、IL-1B等靶点位居前列,PPARA信号通路、晚期糖基化终产物-晚期糖基化终产物受体(AGE/RAGE)信号通路、脂质代谢与动脉粥样硬化及非酒精性脂肪性肝病富集通路位居前列。细胞实验表明,丹荷颗粒可显著降低活性氧(ROS)、丙二醛(MDA)水平,升高过氧化氢酶(CAT)水平(
P
<
0.05),减少HepG2细胞内脂质积累和甘油三酯(TG)含量。动物实验显示,丹荷颗粒能显著降低混合型高脂血症大鼠总胆固醇(TC)、TG和低密度脂蛋白胆固醇(LDL-C)水平(
P
<
0.05),降低MDA水平,升高超氧化物歧化酶(SOD)、CAT水平。减轻肝脏脂肪变性,上调肝脏过氧化物酶体增殖物启动受体
α
(PPAR
α
)和脂蛋白脂肪酶(LPL)的表达,下调固醇调节元件结合蛋白1(SREBP1)的表达(
P
<
0.05,
P
<
0.01)。
结论
2
丹荷颗粒可以通过降低MDA,升高SOD、CAT的水平,消除过量的ROS,抑制氧化应激,并减轻肝损伤,同时上调PPAR
α
、LPL表达水平,抑制SREBP1表达水平,改善脂质代谢紊乱。
Objective
2
To investigate the therapeutic mechanism of Danhe granules in treating mixed hyperlipidemia based on network pharmacology, as well as animal and cell experiments.
Methods
2
The active compounds and targets of Danhe granules were screened using the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) and the Encyclopedia of Traditional Chinese Medicine (ETCM). Related targets for mixed hyperlipidemia were obtained from the GeneCards database. The intersecting targets were subjected to Gene Ontology (GO) functional annotation and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. A high-fat model was established in human hepatocellular carcinoma cells (HepG2) induced by palmitic acid (PA), followed by intervention with Danhe granules to assess intracellular lipid accumulation and oxidative stress levels. A mixed hyperlipidemia rat model was also established and divided into low-, medium-, and high-dose Danhe granules groups (1.134, 2.268, and 4.536 g·kg
-1
, respectively), as well as a positive control group treated with pravastatin sodium (4.020 mg·
kg
-1
). After eight weeks of intervention, serum lipid levels, inflammatory factors, oxidative stress indices, and the expression of key hepatic lipid metabolism-related proteins were determined.
Results
2
Network pharmacology identified 93 intersecting targets between Danhe granules and mixed hyperlipidemia, with peroxisome proliferator-activated receptor gamma (PPARG), peroxisome proliferator-activated receptor alpha (PPARA), tumor necrosis factor (TNF), interleukin-6 (IL-6), and IL-1B among the key nodes. The PPAR signaling pathway, AGE/RAGE signaling pathway, lipid metabolism, atherosclerosis and non-alcoholic fatty liver disease (NAFLD) were among the most significantly enriched pathways. Cellular experiments demonstrated that Danhe granules significantly reduced reactive oxygen species (ROS) and malondialdehyde (MDA) levels while increasing catalase (CAT) activity (
P
<
0.05), thereby alleviating intracellular lipid accumulation and triglyceride (TG) content in HepG2. In animal experiments, Danhe granules markedly decreased serum total cholesterol (TC), TG, and low-density lipoprotein cholesterol (LDL-C) levels (
P
<
0.05), reduced hepatic MDA levels, and elevated superoxide dismutase (SOD) and CAT levels. Histological analysis showed alleviation of hepatic steatosis, upregulation of hepatic PPARA and lipoprotein lipase (LPL) expressions, and downregulation of sterol regulatory element-binding protein 1 (SREBP1) expression (
P
<
0.05,
P
<
0.01).
Conclusion
2
Danhe granules improve lipid metabolism disorders in mixed hyperlipidemia by reducing MDA levels, enhancing SOD and CAT activities, scavenging excessive ROS, inhibiting oxidative stress, and mitigating liver injury. The underlying mechanism may involve the upregulation of PPARA and LPL and the suppression of SREBP1 expression.
《混合型高脂血症基层诊疗中国专家共识(2024年)》编写专家组 . 混合型高脂血症基层诊疗中国专家共识(2024年) [J]. 中华全科医师杂志 , 2024 , 23 ( 9 ): 907 - 917 .
Expert Group on Chinese Expert Consensus on the Diagnosis and Treatment of Mixed Hyperlipidemia in Primary Care ( 2024 ).Chinese expert consensus on the diagnosis and treatment of mixed hyperlipidemia in primary care ( 2024 )[J].Chin J Gen Pract, 2024 , 23 ( 9 ): 907 - 917 .
ZHAO S , WANG Y , MU Y , et al . Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China:Results of the DYSlipidemia International Study (DYSIS) [J]. Atherosclerosis , 2014 , 235 ( 2 ): 463 - 469 .
VEKIC J , STROMSNES K , MAZZALAI S , et al . Oxidative stress,atherogenic dyslipidemia,and cardiovascular risk [J]. Biomedicines , 2023 , 11 ( 11 ): 2897 .
SINGH U , JIALAL I . Oxidative stress and atherosclerosis [J]. Pathophysiology , 2006 , 13 ( 3 ): 129 - 142 .
XU D , XIE L , CHENG C , et al . Triglyceride-rich lipoproteins and cardiovascular diseases [J]. Front Endocrinol , 2024 , 15 : 1409653 .
SOBUKAWA Y , HATTA T , FUNAKI D , et al . Safety of combined statin and fibrate therapy:Risks of liver injury and acute kidney injury in a cohort study from the shizuoka kokuho database [J]. Drugs Real World Outcomes , 2024 , 11 ( 2 ): 317 - 330 .
潘绮雪 , 陈奎奎 , 马兆臣 , 等 . 基于体内暴露量的丹荷颗粒质量标志物研究 [J]. 中草药 , 2021 , 52 ( 9 ): 2608 - 2616 .
PAN Q X , CHEN K K , MA Z C , et al . Study on Q-Marker of Danhe granules based on exposure in vivo [J]. Chin Tradit Herb Drugs , 2021 , 52 ( 9 ): 2608 - 2616 .
于彤 , 张珊 , 乔艳芳 , 等 . 多角度探讨丹荷颗粒对于高胆固醇大鼠脾虚证候的改善作用 [J]. 辽宁中医药大学学报 , 2023 , 25 ( 8 ): 10 - 14 .
YU T , ZHANG S , QIAO Y , et al . FInvestigation of the effect of Danhe granule on treating spleen deficiency syndrome in hypercholesterolemia rats [J]. J Liaoning Univ Tradit Chin Med , 2023 , 25 ( 8 ): 10 - 14 .
于彤 , 张珊 , 乔艳芳 , 等 . 丹荷颗粒对高胆固醇血症大鼠肝脏超微结构及SREBP-1、LXR α 、RXRA蛋白表达的影响 [J]. 中国中医药信息杂志 , 2023 , 30 ( 11 ): 80 - 85 .
YU T , ZHANG S , QIAO Y , et al . Effects of Danhe granules on liver ultrastructure and SREBP-1,LXR α ,RXRA proteins expression in hypercholesterolemic rats [J]. Chin J Inf Tradit Chin Med , 2023 , 30 ( 11 ): 80 - 85 .
MATTEO R , ROSARIA M O , LUCIA C , et al . Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes [J]. J Gastroenterol Hepatol , 2009 , 24 ( 5 ): 830 - 840 .
ALNAHDI A , JOHN A , RAZA H . Augmentation of glucotoxicity,oxidative stress,apoptosis and mitochondrial dysfunction in HepG2 cells by palmitic acid [J]. Nutrients , 2019 , 11 ( 9 ): 1979 .
GUNILLA O . Role of lipoprotein lipase in lipid metabolism [J]. Curr Opin Lipidol , 2016 , 27 ( 3 ): 233 - 241 .
MARTINS I V , RIVERS-AUTY J , ALLAN S M , et al . Mitochondrial abnormalities and synaptic loss underlie memory deficits seen in mouse models of obesity and Alzheimer's disease [J]. J Alzheimers Dis , 2017 , 55 ( 3 ): 915 - 932 .
YUN F L , JUN Z H , LI Z , et al . The effects of needling fenglong (ST40) and neiguan (PC6) on IL-17 of ApoE-Gene-Knockout mice's liver [J]. Evid Based Complement Alternat Med , 2014 , 2014 ( 3 ): 691863 .
JOERG H , LUDGER S . Metabolic-associated fatty liver disease and lipoprotein metabolism [J]. Mol Metab , 2021 , 50 : 101238 .
仝小林 , 刘文科 . 论膏浊病 [J]. 中医杂志 , 2011 , 52 ( 10 ): 816 - 818 .
TONG X L , LIU W K . On the disease of Gaozhuo [J]. J Tradit Chin Med , 2011 , 52 ( 10 ): 816 - 818 .
王新陆 . 血浊证的辨证治疗 [J]. 山东中医杂志 , 2007 , 26 ( 1 ): 3 - 5 .
WANG X L . Diagnosis and treatment of syndrome of turbid blood [J]. Shandong J Tradit Chin Med , 2007 , 26 ( 1 ): 3 - 5 .
冯帅霞 , 徐莹 , 韩涵 . 过氧化物酶体增殖物激活受体(PPAR)在肝脏疾病中的作用及潜在意义 [J]. 临床肝胆病杂志 , 2023 , 39 ( 7 ): 1747 - 1753 .
FENG S X , XU Y , HAN H . Role and potential significance of peroxisome proliferator-activated receptors in liver diseases [J] J Clin Hepatol , 2023 , 39 ( 7 ): 1747 - 1753 .
JIN-LIAN L , QIAO-YUN W , HAI-YUN L , et al . Effects of L -carnitine against oxidative stress in human hepatocytes:Involvement of peroxisome proliferator-activated receptor alpha [J]. J Biomed Sci , 2012 , 19 ( 1 ): 32 .
TOMOHIRO Y , TOMOHIRO I , HITOSHI S , et al . Cross-talk between peroxisome proliferator-activated receptor (PPAR) alpha and liver X receptor (LXR) in nutritional regulation of fatty acid metabolism.I.PPARs suppress sterol regulatory element binding protein-1c promoter through inhibition of LXR signaling [J]. Mol Endocrinol , 2003 , 17 ( 7 ): 1240 - 1254 .
FRUCHART J . Peroxisome proliferator-activated receptor- α activation and high-density lipoprotein metabolism [J]. Am J Cardiol , 2001 , 88 ( 12S1 ): 24 - 29 .
BAI X , WANG S , SHU L , et al . Hawthorn leaf flavonoids alleviate the deterioration of atherosclerosis by inhibiting SCAP-SREBP2-LDLR pathway through sPLA2-Ⅱ A signaling in macrophages in mice [J]. J Ethnopharmacol , 2024 , 327 : 118006 .
张丽静 , 艾耀伟 , 王政强 . 荷叶碱防治小鼠高脂血症作用及其机制 [J]. 医药导报 , 2015 , 34 ( 4 ): 440 - 444 .
ZHANG L J , AI Y W , WANG Z Q . Effects of nuciferine on mice with hyperlipidemia and its mechanisms [J]. Her Med , 2015 , 34 ( 4 ): 440 - 444 .
PENG C , YI W , CONG Z , et al . Quercetin ameliorates non-alcoholic fatty liver disease (NAFLD) via the promotion of AMPK-mediated hepatic mitophagy [J]. J Nutr Biochem , 2023 , 120 : 109414 .
ZHIFU C , XINGTAO Z , KWAME F A , et al . Therapeutic application of quercetin in aging-related diseases:SIRT1 as a potential mechanism [J]. Front Immunol , 2022 , 13 : 943321 .
SANDRA P , ÁNGEL M , VICTORIA M G , et al . Quercetin ameliorates dysregulation of lipid metabolism genes via the PI3K/Akt pathway in a diet-induced mouse model of nonalcoholic fatty liver disease [J]. Mol Nutr Food Res , 2015 , 59 ( 5 ): 879 - 93 .
许奇 , 张洪榕 , 阮诺冰 , 等 . 基于人工智能辅助药物质量评价结合药效学研究木犀草素对db/db小鼠糖脂代谢及肝脏氧化应激损伤的作用及机制 [J]. 中国药理学通报 , 2025 , 41 ( 2 ): 323 - 333 .
XU Q , ZHANG H R , RUAN N B , et al . Effects of luteolin on glucose and lipid metabolism and liver oxidative stress injury in db/db mice based on artificial intelligence assisted drug quality evaluation and pharmacodynamics and its mechanisms [J]. Chin Pharmacol Bull , 2025 , 41 ( 2 ): 323 - 333 .
XIANG M , LIN X , CHEN H . Luteolin inhibits ferroptosis of HUVEC by regulating the Sirt1/Nrf2 pathway [J]. Cell Biochem Biophys , 2025 , 83 ( 4 ): 1 - 14 .
YUE Z , ZHANG Y , ZHANG W , et al . Kaempferol alleviates myocardial ischemia injury by reducing oxidative stress via the HDAC3-mediated Nrf2 signaling pathway [J]. J Adv Res , 2024 , 75755 - 75764 .
LEI W , FEI Z , WUXUN P , et al . Preincubation with a low-dose hydrogen peroxide enhances anti-oxidative stress ability of BMSCs [J]. J Orthop Surg Res , 2020 , 15 ( 1 ): 392 - 392 .
ANTONIO A , F M M , SANDRO A . Lipid peroxidation:Production,metabolism,and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal [J]. Oxid Med Cell Longev , 2014 , 2014 : 360438 .
HUI Z , CHAOHUA L , DONG Z , et al . Wuliangye Baijiu but not ethanol reduces cardiovascular disease risks in a zebrafish thrombosis model [J]. NPJ Sci Food , 2022 , 6 ( 1 ): 55 .
SHIQI C , XIAOXIAO W , TONG L , et al . The improvement of cardiac and endothelial functions of Xue-Fu-Zhu-Yu decoction for patients with acute coronary syndrome:A meta-analysis of randomized controlled trials [J]. Evid Based Complement Alternat Med , 2022 , doi: 10.1155/2022/2671343 http://dx.doi.org/10.1155/2022/2671343 .
0
Views
39
下载量
0
CSCD
Publicity Resources
Related Articles
Related Author
Related Institution
京公网安备11010802024621